Targeting glutamate to treat schizophrenia: lessons from recent clinical studies

Psychopharmacology

Volumn 233, Issue 13, 2016, Pages 2425-2428

  Beck, Katherine ^a   Javitt, Daniel C ^b,c   Howes, Oliver D ^a,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BITOPERTIN; CLOZAPINE; GLUTAMIC ACID; GLYCINE; GLYCINE TRANSPORTER 1; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; POMAGLUMETAD METHIONIL; RG 7118; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BINDING SITE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; HUMAN; MONOTHERAPY; NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; GLUTAMIC ACID; HUMANS; SCHIZOPHRENIA;

EID: 84969894723     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4318-6     Document Type: Editorial

References (27)

1. Beck K, McCutcheon R, Bloomfield MA, Gaughran F, Reis Marques T, MacCabe J, Selvaraj S, Taylor D, Howes OD (2014) The practical management of refractory schizophrenia—the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatr Scand 130(6):427–438
2. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT (2007) The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164(10):1593–1602
3. Bugarski-Kirola D, Wang A, Abi-Saab D, Blattler T (2014) A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia—results from the CandleLyte study. Eur Neuropsychopharmacol 24(7):1024–1036
4. Coyle JT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3(5):241–253
5. Danysz W, Parsons CG (1998) Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50(4):597–664
6. Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK (2014) Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry 75(5):e11–e13
7. Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, Stone JM (2012) Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 37(11):2515–2521
8. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169(5):610–617
9. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56(1):29–36
10. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC (2004) High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55(2):165–171
11. Hofmann C, Pizzagalli F, Boetsch C, Alberati D, Ereshefsky L, Jhee S, Patat A, Boutouyrie-Dumont B, Martin-Facklam M (2016) Effects of the glycine reuptake inbitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers. Psychopharmacology. doi: 10.1007/s00213-016-4317-7
12. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull 35(3):549–562
13. Howes OD, Kapur S (2014) A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry 205(1):1–3
14. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10):1301–1308
15. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151(8):1234–1236
16. Javitt DC, Duncan L, Balla A, Sershen H (2005) Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 10(3):275–287
17. Kinon, B. J., L. Zhang, B. A. Millen, O. O. Osuntokun, J. E. Williams, S. Kollack-Walker, K. Jackson, L. Kryzhanovskaya, N. Jarkova and H. S. Group (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31(3):349–355
18. Kleckner NW, Dingledine R (1988) Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241(4867):835–837
19. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199–214
20. Lencz T, Malhotra AK (2015) Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Mol Psychiatry 20(7):820–826
21. Li ML, Hu XQ, Li F, Gao WJ (2015) Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: still promising or a dead end? Prog Neuropsychopharmacol Biol Psychiatry 60:66–76
22. Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N, Waldman A, Turkheimer FE, Egerton A, Stone J, Howes OD (2015) Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Bull, Schizophr
23. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13(9):1102–1107
24. Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR (2014) Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 19(1):20–29
25. Singer P, Dubroqua S, Yee BK (2015) Inhibition of glycine transporter 1: the yellow brick road to new schizophrenia therapy? Curr Pharm Des 21(26):3771–3787
26. Supplisson S, Bergman C (1997) Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci 17(12):4580–4590
27. Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L (2014) Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 71(6):637–646